BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24448154)

  • 1. Genetic polymorphisms and plasma levels of tissue factor and tissue factor pathway inhibitor in venous thromboembolism.
    Kwon A; Jo SH; Jo YA; Park JY; Kim M; Kang HJ; Kim HS; Cho HC; Lee YK
    Blood Coagul Fibrinolysis; 2014 Jul; 25(5):416-21. PubMed ID: 24448154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Association of single nucleotide polymorphisms of tissue factor and tissue factor pathway inhibitor with venous thromboembolism in patients with lung cancer].
    Zhang XL; Zhu J; Chen WH; Zhai ZG; Zhang YH
    Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(12):901-906. PubMed ID: 29665662
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk.
    Abu Saadeh F; Norris L; O'Toole S; Mohamed BM; Langhe R; O'Leary J; Gleeson N
    Thromb Res; 2013 Nov; 132(5):627-34. PubMed ID: 24094893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
    Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
    Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction].
    Xiong SL; Wang Q; Zheng L; Li JL; Wen ZB; He SL
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1821-3. PubMed ID: 18158992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.
    Dennis J; Truong V; Aïssi D; Medina-Rivera A; Blankenberg S; Germain M; Lemire M; Antounians L; Civelek M; Schnabel R; Wells P; Wilson MD; Morange PE; Trégouët DA; Gagnon F
    J Thromb Haemost; 2016 Oct; 14(10):1960-1970. PubMed ID: 27490645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M; Gori AM; Fedi S; Chiarugi L; Simonetti I; Dabizzi RP; Prisco D; Pepe G; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes of tissue factor and tissue factor pathway inhibitor in neonatal jaundice due to infection].
    Yue SJ; Zhong L; He XF; Yang YJ; Jiang L; He SL; Li JC
    Zhonghua Er Ke Za Zhi; 2003 Feb; 41(2):104-6. PubMed ID: 14759309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
    Shimura M; Wada H; Wakita Y; Nakase T; Hiyoyama K; Nagaya S; Mori Y; Shiku H
    Am J Hematol; 1996 Jul; 52(3):165-70. PubMed ID: 8756081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
    Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
    Lizakowski S; Zdrojewski Z; Jagodzinski P; Rutkowski B
    Scand J Urol Nephrol; 2007; 41(3):237-42. PubMed ID: 17469034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue factor and tissue factor pathway inhibitors TFPI and TFPI2 in human secretory endometrium--possible link to female infertility.
    Altmäe S; Salumets A; Bjuresten K; Kallak TK; Wånggren K; Landgren BM; Hovatta O; Stavreus-Evers A
    Reprod Sci; 2011 Jul; 18(7):666-78. PubMed ID: 21421890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden.
    Lincz LF; Adams MJ; Scorgie FE; Thom J; Baker RI; Seldon M
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):559-64. PubMed ID: 17762532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels.
    Naumnik B; Borawski J; Chyczewski L; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 2006 Dec; 21(12):3450-7. PubMed ID: 16982632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy.
    Opstad TB; Eilertsen AL; Høibraaten E; Skretting G; Sandset PM
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):516-21. PubMed ID: 20453636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of tissue factor -603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients.
    Eroğlu A; Ceylan GG; Ozturk E; Yalcin A; Yalcin B; Karasoy D
    Exp Oncol; 2016 Sep; 38(3):187-90. PubMed ID: 27685527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of plasma tissue factor and tissue factor pathway inhibitor levels in childhood hemangiomas.
    Türker M; Irken G; Oren H; Yilmaz S; Yüksel F; Olgun N
    Pediatr Blood Cancer; 2006 Dec; 47(7):914-7. PubMed ID: 16395682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
    Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
    Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients.
    Teng Y; Jiang R; Lin Q; Ding C; Ye Z
    Thromb Res; 2010 Jul; 126(1):e41-5. PubMed ID: 20226500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyte tissue factor response is decreased in patients with hyperlipidemia.
    Rugeri L; Susen S; Bard JM; Corseaux D; Gavériaux V; Devos P; Lecerf JM; Duriez P; Jude B
    Thromb Res; 1999 Nov; 96(4):283-92. PubMed ID: 10593431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.